TY - JOUR
T1 - Therapeutic considerations for disease progression in multiple sclerosis
T2 - Evidence, experience, and future expectations
AU - Frohman, Elliot
AU - Stuve, Olaf
AU - Havrdova, Eva
AU - Corboy, John
AU - Achiron, Anat
AU - Zivadinov, Robert
AU - Sorensen, Per Soelberg
AU - Phillips, J. Theodore
AU - Weinshenker, Brian
AU - Hawker, Kathleen
AU - Hartung, Hans Peter
AU - Steinman, Lawrence
AU - Zamvil, Scott
AU - Cree, Bruce A C
AU - Hauser, Stephen
AU - Weiner, Howard
AU - Racke, Michael K.
AU - Filippi, Massimo
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2005/10
Y1 - 2005/10
N2 - In the management of patients with multiple sclerosis (MS), providers are all faced with the highly formidable challenge of ascertaining whether, and to what degree, disease-modifying therapy is effective in the individual patient. While much has been learned in randomized, controlled clinical trials, we cannot simply extrapolate the outcomes of these initiatives and apply them to the care of a single patient. In the future, the application of pharmacogenetic techniques, proteomics, and microarray analysis will yield novel profiling information on individual patients that will substantially refine the specific therapeutic questions of relevance: (1) What is the best treatment for an individual patient? (2) Which patients require intensive therapeutic combination regimens to optimize control of the disease process? (3) What are the appropriate drug dosing targets for an individual patient? and (4) Which patients will be predisposed to the development of drug-related adverse events? Such data may provide a novel variable of drug responsiveness that will mandate its inclusion into the process of covariate analyses for clinical trials.
AB - In the management of patients with multiple sclerosis (MS), providers are all faced with the highly formidable challenge of ascertaining whether, and to what degree, disease-modifying therapy is effective in the individual patient. While much has been learned in randomized, controlled clinical trials, we cannot simply extrapolate the outcomes of these initiatives and apply them to the care of a single patient. In the future, the application of pharmacogenetic techniques, proteomics, and microarray analysis will yield novel profiling information on individual patients that will substantially refine the specific therapeutic questions of relevance: (1) What is the best treatment for an individual patient? (2) Which patients require intensive therapeutic combination regimens to optimize control of the disease process? (3) What are the appropriate drug dosing targets for an individual patient? and (4) Which patients will be predisposed to the development of drug-related adverse events? Such data may provide a novel variable of drug responsiveness that will mandate its inclusion into the process of covariate analyses for clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=25144485958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=25144485958&partnerID=8YFLogxK
U2 - 10.1001/archneur.62.10.1519
DO - 10.1001/archneur.62.10.1519
M3 - Review article
C2 - 16216934
AN - SCOPUS:25144485958
SN - 0003-9942
VL - 62
SP - 1519
EP - 1530
JO - Archives of neurology
JF - Archives of neurology
IS - 10
ER -